FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230484734> ?p ?o ?g. }

• W4230484734 endingPage "706" @default.
• W4230484734 startingPage "705" @default.
• W4230484734 abstract "We thank Dr. Dai et al. for their interest in our article and for supporting our findings that liver biopsy does not usually affect the decision for treatment in hepatitis B e antigen (HBeAg)-negative patients with abnormal alanine aminotransferase (ALT) and hepatitis B virus (HBV) DNA ≥ 20,000 IU/mL, although it offers valuable information for patients receiving long-term therapies. There is also no disagreement on the need for biopsy in HBeAg-negative patients with persistently or transiently abnormal ALT and HBV DNA < 20,000 IU/mL. The optimal management of HBeAg-negative patients with persistently normal ALT (PNALT) has always been debatable. We intentionally did not perform biopsies in such patients with HBV DNA ≤ 2000 IU/mL, because we believe that only cases with HBV DNA > 2000 IU/mL represent a controversial group with some likelihood of significant histological lesions. There was no selection bias in our study because there was no patient with PNALT and HBV DNA ≥ 20,000 IU/mL during the inclusion period. Such patients are extremely rare in Greece.1, 2 Among the last 300 HBeAg-negative PNALT patients seen at our clinics, <1% had HBV DNA > 20,000 IU/mL (<200,000 IU/mL, minimal necroinflammation and fibrosis in both cases). We have previously commented on the recent definition of “inactive carriers”,3 which does not include PNALT patients with HBV DNA > 2000 IU/mL [however, such patients are not included under any term in recent guidelines4, 5]. Regarding the conflicting reports on histology and HBV DNA > 20,000 IU/mL in HBeAg-negative PNALT patients, we believe that there are two main reasons. First and most important, not all studies use the same criteria for defining PNALT (a less strict follow-up increases the likelihood of misclassifying patients with ALT fluctuations). We used a strict first-year follow-up with five ALT determinations (every 3 months), while three or fewer ALT determinations (every 6 months) were sufficient for PNALT cases in a study from India (only two ALT values required for inclusion)6 or the United States,7 and no relevant information is provided in a study from Taiwan.8 Second, differences in viral (e.g., genotypes) or host genetic characteristics might be also responsible for such discrepancies; data different from ours are reported in non-European studies.6-8 Inactive carriers represented <8.4% of chronic HBV cases in the study from India,6 whereas they represent a large proportion of chronic HBV European patients. Our data are in agreement with another European (French) study9 including 85 PNALT patients under strict ALT follow-up; HBV DNA > 20,000 IU/mL was exceptionally rare (2%), necroinflammation score was always ≤6, and Ishak fibrosis score was ≤2 in 91% (score 3-4 in 5 of 58 cases). We also agree with Feld et al. that HBV DNA > 20,000 IU/mL is highly predictive of future ALT elevation,10 as we have reported an increased risk of future reactivation in HBeAg-negative PNALT patients with HBV DNA levels of even >2000 IU/mL.2 In conclusion, we believe that our findings are valid and support the suggestion that HBeAg-negative patients with HBV DNA < 20,000 IU/mL and PNALT under strict follow-up, at least in Europe, will not benefit from liver biopsy, which is not expected to show significant lesions. All such cases should be followed for life, whereas patients with HBV DNA > 2000 IU/mL warrant closer follow-up. George V. Papatheodoridis*, Emanuel K. Manesis*, Spilios Manolakopoulos*, Ioannis S. Elefsiniotis , John Goulis , Athanasios J. Archimandritis*, * Second Department of Internal Medicine, Athens University Medical School, “Hippokration” General Hospital of Athens; Greece, University Department of Internal Medicine, “Helena Venizelou” Hospital, Athens; Greece, Fourth Department of Medicine, Aristotelian University of Thessaloniki, Hippokration General Hospital of Thessaloniki; Greece." @default.
• W4230484734 created "2022-05-11" @default.
• W4230484734 creator A5016318276 @default.
• W4230484734 creator A5030128305 @default.
• W4230484734 creator A5046139233 @default.
• W4230484734 creator A5061074754 @default.
• W4230484734 creator A5062306711 @default.
• W4230484734 creator A5088143086 @default.
• W4230484734 date "2008-12-11" @default.
• W4230484734 modified "2023-09-27" @default.
• W4230484734 title "Reply:" @default.
• W4230484734 cites W1970492518 @default.
• W4230484734 cites W1972774048 @default.
• W4230484734 cites W2024797229 @default.
• W4230484734 cites W2071805414 @default.
• W4230484734 cites W2073466847 @default.
• W4230484734 cites W2088351702 @default.
• W4230484734 cites W2093825271 @default.
• W4230484734 cites W2156015715 @default.
• W4230484734 cites W2172106127 @default.
• W4230484734 doi "https://doi.org/10.1002/hep.22780" @default.
• W4230484734 hasPublicationYear "2008" @default.
• W4230484734 type Work @default.
• W4230484734 citedByCount "2" @default.
• W4230484734 countsByYear W42304847342015 @default.
• W4230484734 crossrefType "journal-article" @default.
• W4230484734 hasAuthorship W4230484734A5016318276 @default.
• W4230484734 hasAuthorship W4230484734A5030128305 @default.
• W4230484734 hasAuthorship W4230484734A5046139233 @default.
• W4230484734 hasAuthorship W4230484734A5061074754 @default.
• W4230484734 hasAuthorship W4230484734A5062306711 @default.
• W4230484734 hasAuthorship W4230484734A5088143086 @default.
• W4230484734 hasBestOaLocation W42304847341 @default.
• W4230484734 hasConcept C126322002 @default.
• W4230484734 hasConcept C203014093 @default.
• W4230484734 hasConcept C2522874641 @default.
• W4230484734 hasConcept C2775934546 @default.
• W4230484734 hasConcept C2775940106 @default.
• W4230484734 hasConcept C2777382497 @default.
• W4230484734 hasConcept C2777410769 @default.
• W4230484734 hasConcept C2777766500 @default.
• W4230484734 hasConcept C2780593183 @default.
• W4230484734 hasConcept C71924100 @default.
• W4230484734 hasConcept C90924648 @default.
• W4230484734 hasConceptScore W4230484734C126322002 @default.
• W4230484734 hasConceptScore W4230484734C203014093 @default.
• W4230484734 hasConceptScore W4230484734C2522874641 @default.
• W4230484734 hasConceptScore W4230484734C2775934546 @default.
• W4230484734 hasConceptScore W4230484734C2775940106 @default.
• W4230484734 hasConceptScore W4230484734C2777382497 @default.
• W4230484734 hasConceptScore W4230484734C2777410769 @default.
• W4230484734 hasConceptScore W4230484734C2777766500 @default.
• W4230484734 hasConceptScore W4230484734C2780593183 @default.
• W4230484734 hasConceptScore W4230484734C71924100 @default.
• W4230484734 hasConceptScore W4230484734C90924648 @default.
• W4230484734 hasIssue "2" @default.
• W4230484734 hasLocation W42304847341 @default.
• W4230484734 hasOpenAccess W4230484734 @default.
• W4230484734 hasPrimaryLocation W42304847341 @default.
• W4230484734 hasRelatedWork W1865192122 @default.
• W4230484734 hasRelatedWork W1943054746 @default.
• W4230484734 hasRelatedWork W1974313397 @default.
• W4230484734 hasRelatedWork W1989286830 @default.
• W4230484734 hasRelatedWork W2121477244 @default.
• W4230484734 hasRelatedWork W2123661325 @default.
• W4230484734 hasRelatedWork W2355866703 @default.
• W4230484734 hasRelatedWork W2372551042 @default.
• W4230484734 hasRelatedWork W2373048719 @default.
• W4230484734 hasRelatedWork W2381250083 @default.
• W4230484734 hasVolume "49" @default.
• W4230484734 isParatext "false" @default.
• W4230484734 isRetracted "false" @default.
• W4230484734 workType "article" @default.